Main Article Content
The development of personalized medicine has created a strong demand for biomarkers that can be used in the context of patient diagnosis, monitoring and stratification. At the same time, the quest for new biomarkers has been revived by the emergence of new broadband technologies as well as the development of systemic approaches to study the pathophysiology of diseases such as cancer.According to the National Institutes of Health, a biomarker (or biological marker) is defined as "A biological characteristic measured objectively and evaluated as an indicator of normal or pathological biological processes or pharmacological responses to a therapeutic intervention". Escherichia coli is responsible for the development of various types of diseases, one of the most prevalent in society is urinary tract infection, which affects both sexes and all ages, with a higher prevalence among women. This bacterium can be classified according to clinical manifestations, epidemiology, virulence factor of the strain and anatomical site of the infection. This pathology can be asymptomatic or symptomatic. The complexity of this, in the case of uropathogenic E. coli , will vary according to the host's immunity, bacterial load and virulence factor, with fimbriae being the most important factor in the case of UTI, as they present end H adhesins that mediate the link between host receptor glycoproteins and the bacteria.A biomarker can therefore be molecular, anatomical, physiological or biochemical.More precisely, a tumor marker is defined as "a molecule, a process or a substance altered quantitatively or qualitatively under precancerous or cancerous conditions, the modification being detectable by an analysis". These alterations can come from the tumor itself or from the surrounding normal tissue.Biomarkers are used in two main areas. In biomedical research, biomarkers can be used when developing and evaluating new therapies.